- Home
- ORIC vs SPRY Comparison
ORIC vs SPRY Comparison
Compare ORIC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORIC | SPRY |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ORIC | SPRY |
|---|---|---|
| Price | $13.82 | $9.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 2 |
| Target Price | $20.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 1.3M | 889.4K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.67 | ★ 114.04 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $89,149,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $119.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 297063.34 |
| 52 Week Low | $3.90 | $6.66 |
| 52 Week High | $14.93 | $18.63 |
Technical Indicators
Market Signals| Indicator | ORIC | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 68.79 | 42.09 |
| Support Level | $11.50 | $8.61 |
| Resistance Level | $13.83 | $10.44 |
| Average True Range (ATR) | 0.93 | 0.44 |
| MACD | 0.18 | 0.03 |
| Stochastic Oscillator | 89.56 | 40.31 |
Price Performance
Historical ComparisonAbout ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.